Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy

• Published in: Clinical and experimental immunology 2023-06, Vol.212 (3), p.239-248
• Main Authors: Hsu, Shu-Jung, Chao, Yen-Cheng, Lin, Xia-Hui, Liu, Hua-Hua, Zhang, Yang, Hong, Wei-Feng, Chen, Mao-Pei, Xu, Xin, Zhang, Lan, Ren, Zheng-Gang, Du, Shi-Suo, Chen, Rong-Xin
• Format: Article
• Language: English
• Subjects: Antibodies, Antinuclear; Antineoplastic Agents, Immunological; Cancer Immunity; Humans; Immune System Diseases - chemically induced; Liver Neoplasms - drug therapy; Nivolumab - adverse effects; Retrospective Studies
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1093/cei/uxad036

Abstract Immune-related adverse events (irAEs) clinically resemble autoimmune diseases, indicating autoantibodies could be potential biomarkers for the prediction of irAEs. This study aimed to assess the predictive value of peripheral blood antinuclear antibody (ANA) status for irAEs, considering the time and severity of irAEs, as well as treatment outcome in liver cancer patients administered anti-PD-1 therapy. Ninety-three patients with advanced primary liver cancer administered anti-PD-1 treatment were analyzed retrospectively. They were divided into the ANA positive (ANA+, titer ≥ 1:100) and negative (ANA-, titer < 1:100) groups. Development of irAEs, progression-free survival (PFS), and overall survival (OS) were assessed. Compared with ANA- patients, ANA+ cases were more prone to develop irAEs (43.3% vs. 19.2%, P = 0.031). With the increase of ANA titers, the frequency of irAEs increased. The time interval between anti-PD-1 therapy and the onset of irAEs was significantly shorter in ANA+ patients compared with the ANA- group (median, 1.7 months vs. 5.0 months, P = 0.022). Moreover, the time between anti-PD-1 therapy and irAE occurrence decreased with increasing ANA titer. In addition, PFS and OS were decreased in ANA+ patients compared with the ANA− group (median PFS, 2.8 months vs. 4.2 months, P = 0.043; median OS, 21.1 months vs. not reached, P = 0.041). IrAEs occur at higher frequency in ANA+ liver cancer patients undergoing anti-PD-1 therapy. ANA titer could help predict irAE development and treatment outcome in these patients. Immune-related adverse events (irAEs) occur at higher frequency in ANA+ liver cancer patients undergoing anti-PD-1 therapy. Graphical Abstract Graphical Abstract